The Safety and Efficacy of GLP-1 Receptor Agonists in Heart Failure Patients: A Systematic Review and Meta-Analysis

Area of Science:

• Cardiology
• Endocrinology
• Pharmacology

Background:

• Heart failure (HF) affects millions globally, with limited treatment options, especially for those with co-existing type 2 diabetes mellitus (T2DM).
• Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have shown cardiovascular benefits in T2DM patients, prompting investigation into their role in HF.
• Evaluating GLP-1 RA efficacy and safety in HF patients with or without T2DM is crucial for expanding therapeutic strategies.

Approach:

• A meta-analysis was conducted, pooling data from 9 randomized controlled trials (RCTs) involving 871 participants.
• The study assessed the impact of GLP-1 RAs compared to placebo on major adverse cardiovascular events (MACE), including cardiovascular mortality and HF hospitalizations.
• Secondary outcomes included changes in left ventricular ejection fraction (LVEF) and the 6-minute walk test (6MWT).

Key Points:

• GLP-1 RAs did not significantly improve the primary outcome of MACE, cardiovascular mortality, or HF hospitalizations compared to placebo.
• No significant improvements were observed in secondary outcomes, such as LVEF or 6MWT performance.
• The analysis included patients with HF, both with and without T2DM.

Conclusions:

• Current evidence suggests GLP-1 RAs do not offer significant cardiovascular benefits for patients with heart failure, irrespective of their diabetes status.
• Further research may be needed to explore specific subgroups or alternative mechanisms.
• The findings indicate that GLP-1 RAs are not currently a recommended treatment for improving cardiovascular outcomes in this patient population.